Here's why the Imugene (ASX:IMU) share price opened 8% higher today

The Imugene Limited (ASX: IMU) share price is on the move today after news from the company on its HER-Vaxx's clinical trial.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Imugene Limited (ASX: IMU) shares are on the rise today after news from the company on its HER-Vaxx's clinical trial. The Imugene share price opened today's session 8.15% higher at 20 cents before climbing to an intraday high of 21.5 cents. At the time of writing, the company's shares have retreated back to 19 cents, up 2.7%.

Let's take a closer look at today's news from Imugene.

What's boosting the Imugene share price? 

The Imugene share price is responding positively after the biotech announced today that the second clinical endpoint for its HER-Vaxx clinical studies has been met.

HER-Vaxx is an immunotherapy to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The first clinical end point was overall patient survival, while the second was progression-free survival (PFS).

The company states its second clinical endpoint has been met, as a statistically significant amount of PFS has occurred.

The trial is the second phase of HER-Vaxx trials. It's being conducted in multiple sites across Eastern Europe and India, where clinicians have difficulty accessing antibody treatments and there are high levels of gastric cancer.

Data from 24 PFS events will now be analysed. The company stated final PFS results are expected in the coming months.

Commentary from management

Imugene managing director and CEO Leslie Chong commented on the company's news. She said:

I am delighted to report that we have achieved this new significant milestone for patients with advanced gastric cancer, following on from the important interim data released in 2020 and new data presented at AACR earlier this month. I look forward to updating the market as the data is analysed.

Imugene share price snapshot

Imugene shares have been having a roaring time on the ASX lately.

Currently, the Imugene share price is up by 90% year to date. It's also up by 850% over the last 12 months.

The company has a market capitalisation of around $881 million, with approximately 4.7 million shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned.

The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »